header logo image

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of…

December 5th, 2023 2:51 am

PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the State of Tennessee added ZTlido® as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.1 This change has the potential to improve access to ZTlido® for all eligible patients which includes approximately 1,500,000 adult lives between the ages of 19 to 64.1

Continue reading here:
Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of...

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick